Join our newsletter
Get updated info, tips and news about breastfeeding, e-lactancia project and other initiatives from APILAM
Legitimation: Consent of the interested party
As a user and interested I inform you that the data you provide will be located on the servers of MailChimp (email marketing provider of APILAM) outside the EU in the USA. MailChimp is covered by the EU-US Privacy Shield agreement, whose information is available here, approved by the European Committee for Data Protection. See Mailchimp's privacy policy. (https://mailchimp.com/legal/privacy/).
The fact that you do not enter the personal data that appear on the form as mandatory may have the consequence that we can not meet your request.
You can exercise your rights of access, rectification, limitation and delete the data in apilam.es@gmail.com as well as the right to file a claim with a control authority.
You can consult the additional and detailed information on Data Protection on this website: http://e-lactancia.org, as well as consult our own privacy policy.
A 14-amino acid synthetic peptide related to the endogenous guanylin peptide family.
Administered in moderate-severe constipation from irritable bowel syndrome and in idiopathic chronic constipation.
It acts locally in the intestine, without being absorbed (EMA 2016). It is metabolized in the intestine obtaining its main active metabolite, des-tyrosine. Both linaclotide and des-tyrosine are digested by intestinal enzymes and transformed into natural amino acids.
Since the last update we have not found any published data on its excretion in breast milk.
Its pharmacokinetic data (zero or negligible intestinal absorption with undetectable plasma levels and high molecular weight) make it very unlikely that significant amounts will pass to breast milk (EMA 2016).